ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

rocakinogene sifuplasmid

Also written as “INO-9012”, “INO-9112” and “INO-4212 + INO-9012”.

Its studies are mostly in Glioblastoma · Carcinoma, Transitional Cell · Hepatitis B · Hemorrhagic Fever, Ebola · Breast Neoplasms, led by 2 companies.

Drug pageRocakinogene sifuplasmid: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Apr 2, 20188 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Inovio Pharmaceuticals61 open or runningphase 2since Apr 2, 2018Sep 11, 2014Dec 31, 2027phase 2 · NCT03491683
Geneos Therapeuticsits history only22 open or runningphase 2since Jan 27, 2020Jan 27, 2020Sep 2029phase 2 · NCT07722741

Also a collaborator on its studies: GeneOne Life Science.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Inovio Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 11, 2014First study: phase 1 study in NeoplasmsFirst studyNCT02241369 · 3 enrolled · United States
  2. Apr 21, 2015Phase 1 study in Hepatitis BNCT02431312 · 90 enrolled · United States, Australia, Hong Kong and more
  3. May 28, 2015Phase 1 study in Hemorrhagic Fever, EbolaNCT02464670 · 240 enrolled · United States
  4. Nov 4, 2016Phase 1 study in Breast NeoplasmsNCT02960594 · 93 enrolled · United States
  5. Apr 2, 20182 phase 2 studiesNCT03491683, NCT03502785
  6. Dec 9, 2019Named rocakinogene sifuplasmidINNProposed as its International Nonproprietary Name in WHO's List 122 · before, INO-9012, INO-9112
  7. Oct 22, 2026Primary completion moved from 2026-12-31 to 2027-12-31Date moved laterphase 2 · +12 months · NCT03491683

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in GlioblastomaNCT03491683

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 Inovio Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03502785Carcinoma, Transitional Cell · United States2CompletedMay 9, 202535
NCT03491683Glioblastoma · United States2Active, not recruitingDec 31, 202752
NCT02960594Breast Neoplasms · United States1CompletedNov 9, 201893
NCT02464670Hemorrhagic Fever, Ebola · United States1CompletedMay 24, 2018240
NCT02431312Hepatitis B · United States, Australia, Hong Kong and more1CompletedMay 22, 201890
NCT02241369Neoplasms · United States1CompletedSep 20183

How it is read

Names in the registry

  • “INO-9012”, 5 entries
  • “INO-9112”, 1 entry
  • “INO-4212 + INO-9012”, 1 entry
  • “INO-4201 + INO-9012”, 1 entry
  • “INO-3106, INO-9012”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.